MacroGenics Announces Positive Results from Pivotal Phase 3 SOPHIA Study of Margetuximab

Go back to MacroGenics Announces Positive Results from Pivotal Phase 3 SOPHIA Study of Margetuximab
MACROGENICS (NASDAQ: MGNX) Delayed: 4.15 +0.02 (0.48%)
Previous Close $4.13    52 Week High $36.11 
Open $4.12    52 Week Low $14.84 
Day High $4.17    P/E 10.64 
Day Low $4.09    EPS $0.39 
Volume 123,263